Article
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR).
American journal of respiratory and critical care medicine - 1 Jun 2025
Montani David, McLaughlin Vallerie V, Gibbs J Simon R, Gomberg-Maitland Mardi, Hoeper Marius M, Preston Ioana R, Souza Rogerio, Waxman Aaron B, Escribano Subias Pilar, Feldman Jeremy, Meyer Gisela M, Olsson Karen M, Coulet Florence, Manimaran Solaiappan, Zhao Yujie, Lau Anna, de Oliveira Pena Janethe, Badesch David B, Humbert Marc
Abstract excerpt
Rationale: It is unclear whether carriers of pathogenic variants in PAH-associated genes have a distinct response to PAH treatment. Objectives: To evaluate the effect of genetic variant status on the efficacy of sotatercept and the effect of sotatercept treatment on biomarkers in pulmonary arterial hypertension. Methods: PULSAR (A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension;...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.